Skip to content
Resources > Reports

The Future of Generative AI in Business

The future of artificial intelligence (AI) is now.

No longer is AI and its various iterations sequestered to “high-tech” use cases, but instead, it’s being implemented into day-to-day business operations and decision-making. And while the excitement around generative AI (genAI) is rightly palpable amongst C-Suite executives, a number of important questions remain unanswered.

Which industries are ripe for disruption? What are the risks and unknowns of leaning on genAI for information? What societal behavior changes can be expected?

To gain answers to these pressing questions, we spoke with Eric Schmidt, Co-Founder of Schmidt Futures and Former CEO & Chairman of Google, and David Solomon, Chairman and CEO of Goldman Sachs. Learn what we can expect to see unfold with the rapid growth and implications of genAI in this informative Q&A.

The information contained in this podcast does not constitute a recommendation from any Goldman Sachs entity to the recipient, and Goldman Sachs is not providing any financial, economic, legal, investment, accounting, or tax advice through this podcast or to its recipients.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.